Ona raises $86.6m to advance cancer-targeting ADCs
Ona Therapeutics has announced it has raised $86.6 million to advance its first-in-class antibody-drug conjugates (ADCs) into clinical development.
The biopharmaceutical company raised the money in a Series B financing round, co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys.
Ona says the proceeds will be used to advance the clinical development of Ona’s lead programme, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer.
ONA-255 is designed to address treatment-resistant tumour biology through a differentiated mechanism, aimed at improving the therapeutic index compared to earlier approaches.
Meanwhile, ONA-389 will advance towards first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need.
“The oversubscribed Series B marks an important step to advancing ONA‑255 toward clinical proof of concept in breast cancer, while progressing early clinical development activities for ONA‑389 in colorectal cancer,” said Dr Valerie Vanhooren, Co-Founder and Chief Executive Officer at Ona Therapeutics.
“We are proud to have assembled a high-quality syndicate of investors who share our conviction in the differentiated science behind Ona’s novel targets and their potential to address drug resistance.
“Supported by a highly experienced and talented team, this financing strengthens our commitment to tackling hard-to-treat cancers through meaningful innovation and addressing the significant unmet need faced by patients with limited treatment options.”
